Efficacy and safety analysis of atezolizumab continuation beyond progression in extensive-stage small cell lung cancer.

ABSTRACT: The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC) patients. However, many patients eventually develop resistance to immunotherapy. While continued ICI therapy beyond disease progression has shown survival benefits in various cancers, research specific to ES-SCLC remains limited. Our study aimed to further evaluate the efficacy and safety of atezolizumab continuation therapy to optimize the ICI continuation strategies for ES-SCLC. In this multicenter study, all enrolled patients received continued atezolizumab in combination therapy as second-line (2L) treatment after progression of first-line (1L) chemo-immunotherapy. The efficacy was measured by median overall survival (mOS) and median progress

SUBMITTER: Shi W 

PROVIDER: S-EPMC11880126 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature